Quinolone-resistant Escherichia coli (QREC) strains are being isolated with increasing frequency. From 1993 to 1998, 40 cases of QREC bacteremia were observed in a teaching hospital; 25 episodes (63.5%) were community-acquired. The incidence of QREC bacteremia increased steadily, from 6.7% to 24.6% during 5 years, and correlated with the significantly increased use of fluoroquinolones ( , ). When the 40 P p .003 r p 0.98 QREC bacteremic patients were compared with 80 patients with bacteremia due to quinolone-susceptible E. coli, prior fluoroquinolone use was the only independent risk factor for QREC bacteremia ( ). A high P p .001 APACHE II score was the only independent risk factor for death. The rate of multidrug resistance of QREC was much higher (60%) than that of quinolone-susceptible isolates (13.8%). Pulsed-field gel electrophoresis patterns of these isolates were diverse. Therefore, the isolates revealed little evidence of clonal spread and may have emerged in direct response to the selective pressure exerted by prior fluoroquinolone use.
Fluoroquinolones are potent broad-spectrum antibiotics structurally related to nalidixic acid [1, 2] . The introduction of fluoroquinolones in clinical practice has been associated with an increasing incidence of infection with quinolone-resistant bacteria, especially Staphylococcus aureus [3] and many gram-negative bacilli [4] [5] [6] [7] . However, isolation of quinolone-resistant Escherichia coli (QREC) remained rare until 1990, when the widespread use of fluoroquinolones for treatment of urinary tract infections [8, 9] and for prophylaxis among patients with neutropenia [10] [11] [12] [13] and liver cirrhosis [14] was associated with the emergence of resistant strains. Thus, this situation is evolving, and QREC strains are being isolated with increasing frequency from the community and from the hospital [15, 16] .
Korea University Guro Hospital is a 600-bed teaching hospital in Seoul. Fluoroquinolones were introduced to our hospital in January 1992. Ciprofloxacin or norfloxacin were administrated to patients with cancer who had impending granulocytopenia and to patients with cirrhosis who had prior episodes of spontaneous bacterial peritonitis.
Recently, we have observed a considerable increase in the prevalence of QREC strains isolated from cultures of blood in our hospital. The aim of this study was to analyze the correlation between the consumption of fluoroquinolone and the prevalence of QREC bacteremia in our society, to define the risk and prognostic factors for the acquisition of QREC bacteremia, to estimate the antibiotic susceptibility of QREC isolates to other antibiotic classes, and to investigate the genetic diversity of QREC isolates from the community and hospital. , bars) at Guro Hospital, Korea University, and prevalence of bacteremia due to quinolone-resistant Escherichia coli (QREC) from the community and hospital (Ⅵ), from the hospital ( ), and from the community (ⅷ).
PATIENTS AND METHODS

Patients.
We obtained a computer-generated line listing of patients who were admitted to Korea University Guro Hospital and who had at least 2 blood samples that were positive by culture for E. coli from September 1993 through August 1998. To define the risk factors for the acquisition of QREC bacteremia, a casecontrol study was carried out. Case patients were defined as all patients from whom QREC was isolated from blood during the study period. Two control patients with bacteremia due to quinolone-susceptible E. coli were selected for each case according to the nearest date of a positive blood culture result. We collected demographic data for patients from both groups, such as duration of antibiotic treatment, presence of chronic underlying illness, APACHE II score at the onset of bacteremia, presence of urinary catheter, prior use of fluoroquinolones, prior use of other antibiotic agents, source of bacteremia, resistance to other antibiotic agents, and rate of mortality. Pharmacy records were reviewed. Consumption was expressed as defined daily doses and antibiotic use density (AUD) [17] . One defined daily dose corresponded to norfloxacin for oral use (800 mg), ciprofloxacin for oral use (1 g), or ciprofloxacin for iv use (800 mg). The yearly AUD of each fluoroquinolone was totaled for comparison of the total amounts of yearly fluoroquinolone consumption.
Definitions. Bacteremia was defined as growth of E. coli from у2 sets of blood cultures. Bacteremia was considered to be acquired from the hospital if it developed 48 h after admission and no evidence of infection was present on admission; all other episodes of bacteremia were considered to be acquired from the community. The source of bacteremia was designated as urinary tract, intra-abdominal (e.g., spontaneous bacterial peritonitis), surgical wound, lower respiratory tract, or unknown origin as primary bacteremia, according to criteria published elsewhere [1] [2] [3] [4] [5] [6] . Prior antibiotic use was defined as administration of fluoroquinolone or other antibiotic agents for 148 h during the previous 3 months. The overall mortality rate was calculated based on the number of deaths during hospitalization.
Microbiologic studies. Blood cultures were done by use of an automatic system, Bactec NR-660 (Becton Dickinson). E. coli strains recovered from blood were tested for antimicrobial susceptibility against various antibiotic agents by disk diffusion and agar dilution methods. Based on the criteria of the National Committee for Clinical Laboratory Standards (NCCLS) [18] , the MIC break points for ciprofloxacin were as follows: susceptible, р1 mg/mL; resistant, у4 mg/mL. The MIC break points for other antibiotic agents (ampicillin, gentamicin, amikacin, cefotaxime, trimethoprim-sulfamethoxazole) were those recommended by the NCCLS. Multidrug resistance was defined as resistance to у3 classes of antibiotic agents other than fluoroquinolones.
Selected strains were further characterized by pulsed-field gel electrophoresis (PFGE). DNA for PFGE analysis was prepared by the method of Perrin et al. [19] . Digestion of the agarose blocks was done with XbaI (TaKaRa) in accordance with the manufacturer's instructions. PFGE was done on a CHEF-DR III apparatus (BioRad).
Statistical analysis. Data were analyzed with a statistical software package (SPSS). Contingency tables were analyzed by the 2-tailed x 2 test and continuous variables by Student's unpaired t test. The correlation between the incidence of QREC bacteremia and fluoroquinolone use was calculated by Spearman's correlation coefficient. Univariate analyses were done to determine the risk factors for development of QREC bacteremia. A multivariate analysis was done to assess the independence of statistically significant variables in the univariate analysis, by an unconditional stepwise logistic regression model. A 2-tailed was considered statistically significant. P ! .05
RESULTS
During the study period, 40 (15.7%) of 254 cases of E. coli bacteremia in our hospital were due to QREC strains. The prevalence of QREC strains among all patients with E. coli bacteremia steadily increased, from 6.7% in 1994 to 24.6% in 1998. There was an increase in the community-acquired cases (from 1 [3.3%] of 30 cases in 1994 to 8 [26%] of 31 cases in 1998) and in hospital-acquired cases (from 2 [12%] of 17 cases in 1994 to 6 [25%] of 24 cases in 1998). During the same period, we concomitantly observed a increase in fluoroquinolone consumption in the hospital, from 177.1 to 241.7 AUD (figure 1). There was a statistically significant correlation be- (table 1) . A factor significantly related to the QREC bacteremia was the presence of chronic underlying illness, such as malignancy, hematologic disease, and liver cirrhosis. Case patients were more likely to have a prior episode of spontaneous bacterial peritonitis as the source of bacteremia and significantly associated with recent urinary catheterization. Among the 9 patients with QREC bacteremia with urinary-tract origin, 7 had prior urinary catheterization. Prior use of fluoroquinolones was the important risk factor related to QREC bacteremia. Among the 40 case patients, 8 had previously received iv ciprofloxacin (400 mg/day) and 23 had previously received oral fluoroquinolone (6 patients received norfloxacin, 400 mg/day; 2 patients received norfloxacin, 800 mg/day; 10 patients received norfloxacin, 1 g/day; 5 patients received ofloxacin, 600 mg/day). The modal duration of prior fluoroquinolone use was 20 days among case patients. Among 80 control patients, only 7 received prior oral fluoroquinolone, for 9 days. Prior use of other antibiotic agents and hospital acquisition were also related to QREC bacteremia. In a logistic regression model in which QREC bacteremia was a dependent variable and in which variables were adjusted for univariate analysis, prior use of fluoroquinolones ( ) showed the strongest association with QREC bac-P p .001 teremia.
There was no major difference in the selection of antibiotic agents for the treatment of E. coli bacteremia regardless of quinolone susceptibility. QREC bacteremia was treated with thirdgeneration cephalosporins alone (30 cases) or third-generation cephalosporins with aminoglycosides (10 cases). However, more prolonged duration of treatment was needed in case patients than control patients (mean, 11.2 vs. 9.2 days;
). P p .05 The overall rate of mortality was 30% among case patients and 16% among control patients. There was a trend for case patients to have a higher risk of death ( ), but there was P p .08 no causal relation between the phenotypes of quinolone susceptibility and the prognosis. Death was significantly associated with the presence of chronic underlying illness such as malignancy, prior use of fluoroquinolones, and male sex (table 2) . However, a high APACHE II score was the only independent risk factor for death by multivariate analysis ( ). P p .001 The ciprofloxacin MICs for QREC ranged from 4 to 512 mg/ mL, with a MIC 50 of 64 mg/mL. Of the 40 ciprofloxacin-resistant strains studied, all were cross-resistant to the other available quinolones. MICs for the ciprofloxacin-resistant strains ranged from 8 to 512 mg/mL for ofloxacin and 4 to 256 mg/mL for levofloxacin; MIC 50 s were 32 and 16 mg/mL, respectively. Significant differences in susceptibility to other classes of antibiotics were observed between the quinolone-resistant and quinolone-susceptible strains of E. coli (table 3) . Sixty percent of QREC (24/40) but only 13.8% (11/80) of quinolone-susceptible E. coli strains were resistant to у3 classes of antibiotic agents other than quinolone ( ). P p .001 All QREC isolates from patients with community-acquired and hospital-acquired bacteremia were further characterized by PFGE. Eight different types of PFGE patterns (HA-HH) were observed in 15 QREC isolates from patients with hospitalacquired bacteremia, and 10 different PFGE patterns (CA-CJ) were noted in 25 QREC isolates from patients with communityacquired bacteremia (figure 2). These 2 groups of QREC isolates showed genetic diversity. There was no evidence of clonal spread in the hospital and community, but independent emergence of resistant mutants occurred in our hospital and community.
DISCUSSION
The number of reports about the development of bacterial resistance to fluoroquinolones have increased. Although a variety of species have been included in these studies, the incidence of QREC in large surveys remained extremely low. However, QREC strains recently have been isolated frequently from neutropenic patients and from patients with urinary tract infections [20, 21] . In this study, we found that the incidence of QREC bacteremia increased from 6.7% in 1994 to 24.6% in 1998, particularly among patients with community-acquired disease.
We have seen that the prior use of fluoroquinolones constitutes a major risk factor associated with QREC bacteremia. In fact, there was a statistically significant positive correlation between the increased incidence of QREC bacteremia and the AUD of fluoroquinolones ( ; ). The incidences r p .03 P p .98 of QREC bacteremia among patients with malignancy and liver cirrhosis were much higher than among patients with other underlying diseases, presumably because of the greater risk of acquiring nosocomially transmitted QREC strains during prolonged and repeated periods of admission. However, our study revealed various PFGE patterns of QREC obtained from the hospital and from the community. Therefore, prolonged prophylactic use of fluoroquinolones in those patients may act as an important selective force for the acquisition of QREC mutants rather than acquisition from intrahospital, clonal spread. Our findings concur with those of a recently published study [20] in Spain, which demonstrated that prior exposure of the patients to fluoroquinolones was the single most significant risk factor for the isolation of resistant organisms.
Furthermore, the chance of acquiring QREC bacteremia was statistically higher in nosocomial infection, probably because of the higher probability of having serious underlying diseases and the higher incidence of fluoroquinolone or other antibiotic use compared with the control group.
In previous reports [20, 21] , infections of the urinary tract and those with an intra-abdominal focus were the most frequent sources of QREC bacteremia; spontaneous bacterial peritonitis and primary bacteremia were frequent sources of QREC bacteremia, and urinary tract infection, in our study. APACHE II scores, which represent the severity of bacteremia, were similar in case and control groups in our study. Therefore, we can assume that the susceptibility of E. coli strains to quinolones does not influence the severity of bacteremia.
At the time of writing, there are no reports about the mortality rates of patients with QREC bacteremia compared with bacteremia due to quinolone-susceptible E. coli. In our study, the mortality rate of the patients with QREC bacteremia was slightly higher than that of patients with bacteremia due to quinolone-susceptible E. coli but statistically not significant (30% vs. 16%;
). Therefore, quinolone-resistant strains P p .08 seem not to be more virulent than quinolone-susceptible strains. Poor response to antibiotic agents due to higher multidrug resistance in QREC isolates than in susceptible isolates (60.0% vs. 13.8%; ) contributed to a slightly higher P p .00 mortality rate among patients with QREC bacteremia. Regardless of susceptibility to quinolones, the presence of chronic underlying illness, malignancy, and the prior use of fluoroquinolone were significantly related to higher risk of death.
However, the APACHE II score was only independent risk factor for death in multivariate analysis.
The widespread use of fluoroquinolones in recent years in our hospital may have progressively selected for resistant mutants of E. coli. The high level of resistance of our strains, with MICs ranging 4-512 mg/mL, likely results from 2 independent spontaneous mutations in a target site, such as gyrA, and/or may involve alteration in fluoroquinolone accumulation within the cell [22] [23] [24] [25] . The continued exposure to fluoroquinolones would explain the occurrence of strains with high-level resistance to quinolones in the community.
Moreover, our QREC strains were more often resistant to unrelated antibiotic agents than were quinolone-susceptible E. coli strains. Sixty percent of QREC isolates were resistant to 3 other classes of antimicrobial agents. The real problem of such multidrug-resistant strains is that the use of any one of these antibiotic agents may lead to the selection and maintenance of resistance to other agents as well.
The current risk of developing QREC infection in patients without prior use of quinolones is unknown, although it should be low. However, if mutants of QREC strains in both the community and the hospital became more prevalent, they may replace the normal reservoir of quinolone-susceptible E. coli in a significant number of patients.
Our study has several limitations. The first is that the consumption of quinolones in the community was not evaluated. The second limitation is that we did not investigate the mechanism of quinolone resistance and the cause of multidrug resistance in QREC.
We conclude that neutropenic patients with cancer and patients with cirrhosis receiving fluoroquinolone prophylaxis may be at increased risk of developing QREC bacteremia and that the prior use of fluoroquinolones was the only independent risk factor. In patients with QREC bacteremia, the incidence of multidrug resistance to other classes of antibiotic agents was higher, the duration of treatment with antibiotic agents was longer, and the patients showed slightly higher mortality rates than did those with bacteremia due to quinolone-susceptible E. coli. Therefore, the careful monitoring of patients receiving fluoroquinolone prophylaxis is required. An appropriate use of these drugs should be recommended to reduce the spread of QREC stains.
